Although basic mechanisms of bronchial hyper-responsiveness (BHR) are still incompletely understood, inflammation of airways is likely to play a fundamental role in modulating BHR in patients with asthma. The involvement of several inflammatory cells (eosinophils, mast cells, lymphocytes, neutrophils, macrophages and platelets) and of bioactive mediators secreted by these cells in the pathogenesis of asthma is well documented. Sodium cromoglycate and nedocromil sodium are two pharmacological agents which have anti-allergic and anti-inflammatory properties. Their clinical effectiveness in mild to moderate asthma, and the capacity to reduce BHR under different natural and experimental conditions, make them valuable drugs for maintenance therapy in patients with asthma.

Keywords: Airway reactivity, Bronchial hyper-responsiveness, Cromoglycate, Nedocromil

Bronchial Hyper-responsiveness

Bronchial hyper-responsiveness (BHR) is defined as an abnormal responsiveness of the airways which determines an increased air flow obstruction on exposure to different stimuli. Classically, these stimuli have been divided into specific stimuli such as allergens and chemicals, and non-specific stimuli such as histamine, methacholine, cold air and exercise. Nevertheless, this classification does not seem completely adequate since the so-called non-specific stimuli also act through different and specific mechanisms. Although some authors feel that BHR is acquired during life, there is evidence that constitutional and familial or genetic factors play a major role in predisposing to BHR. The risk of BHR is related to the degree and the severity of atopy. In allergic asthmatics, BHR increases during prolonged exposition to inhaled allergens (e.g. during the pollen season) and significantly decreases after adequate environmental control. There is also a strong association between the degree of BHR and asthma severity and medication requirement, and BHR is considered to be a risk factor for the outcome of childhood asthma.

Although the factors that may contribute to BHR are still incompletely known, there is today strong evidence that the inflammatory process that occurs in the airways in asthma is the key event in the modulation of BHR. Studies on bronchial alveolar lavage (BAL), sputum or bronchial biopsies in subjects with asthma are all consistent with the involvement of eosinophils, mast cells, lymphocytes, neutrophils, macrophages and platelets in airway inflammation. Consequently, a variety of inflammatory mediators are locally active, such as histamine, prostanoids, leukotrienes, kinins, eosinophil proteins, mast cell tryptase and neuropeptides. The role of mast cells seems to be of the greatest importance in the initial phases of allergic inflammation. Two populations of these cells have so far been identified in human lungs. One is located near blood vessels and fibrous stroma, and can be studied only after enzymatic dissociation of whole lung tissue. The second population is between the basement membrane and the epithelium, and can be easily recovered in BAL. The two types of pulmonary mast cells show subtle functional differences, and they probably play distinct roles in the pathogenesis of asthma. Because of their location, BAL mast cells would come into immediate contact with inhaled allergens and consequently might be involved in the initial events of the asthmatic response. The number of BAL mast cells is increased in subjects with asthma and it correlates with the degree of airway obstruction and hypersensitivity.

The inflammatory response and mediator release might influence BHR through the increase of airway epithelial permeability, the decrease in airway calibre, and the modification of autonomic control or myogenic function. Viral infections and ozone, which cause reversible damage of the airway epithelium, also result in a transient increase of bronchial reactivity. Recently, it has been shown that inflammation also occurs in the airways of mildly asthmatic patients with normal pulmonary function but with BHR to histamine or methacholine.

With respect to the ability to induce airway inflammation, the different stimuli can be divided into two groups. The first group includes allergens, occupa-
tional chemical substances (such as isocyanates), and
certain viral infections which can cause both airway
constriction and airway inflammation. The second
group of stimuli includes histamine, methacholine,
exercise, cold air and hypertonic solutions which are
responsible for a substantial bronchoconstriction.
Airway response to these stimuli is strongly influ-
enced by the degree of pre-existent inflammation.

Allergen inhalation in subjects with asthma causes,
at 10–15 min interval, an early asthmatic response
which is frequently (70% or more in children) fol-
lowed by a late bronchoconstriction that peaks at
6–12 h after the challenge.19 This late asthmatic
response (LAR) is strongly connected with the cellu-
lar phase of airway inflammation, and is particularly
associated with an increase in bronchial reactivity to
histamine and methacholine which may last several
days or weeks.21–23 We can assume that the increase
of bronchial reactivity to histamine or methacholine
indirectly reflects the degree of airway inflammation
in asthma.1

Based on the concept that inflammatory processes
are of paramount importance in modulating bron-
chial reactivity and clinical symptoms, in patients
with chronic asthma it makes sense to use preferen-
tially those drugs that treat the underlying disease
because of their anti-inflammatory activity. Presently,
there is sufficient evidence to suggest that β₂-
agonists, anticholinergic drugs and xanthines have
little, if any, anti-inflammatory activity, and that they
have no significant long-term effects on airway reac-
tivity.24 On the other hand, drugs with an appreciable
anti-inflammatory activity are already available
(corticosteroids, sodium cromoglycate, nedocromil
sodium) and other anti-inflammatory medications
(cyclosporin, leukotriene antagonists, 5-lipoxy-
genase inhibitors, platelet activating factor receptor
blockers) are being studied in the treatment of severe
asthma.25 In the following paragraphs, we will focus
on the role of sodium cromoglycate and nedocromil
sodium in inducing modifications of BHR and of the
underlying inflammatory processes.

Sodium Cromoglycate

Since its discovery, sodium cromoglycate (SCG)
was found to have minimal bronchodilatory effect in
both animal and human models, while it showed
significant activity in modulating inflammatory
events involved in the pathogenesis of allergic dis-
ases. In the past 30 years a large amount of research
has been devoted to the study of the biological and
clinical effects of SCG. Nevertheless, the basic
mechanisms of action of this drug are not completely
understood.26 At present, there is a reasonable con-
sensus on at least some aspects of the activity of SCG
(Table 1). The first and the most extensively studied
mechanisms are the stabilization of mast cell mem-

branes and the inhibition of histamine release during
antigen challenge. Very high concentrations of SCG
are required to prevent degranulation of mast cells
from dispersed lung tissue,27 while concentrations
which are clinically achievable are effective in inhib-
iting BAL mast cell degranulation.28 This effect on
mast cell degranulation is thought to be dependent
on two main molecular events: blockage of
extracellular calcium shift into the cell and
phosphorylation of specific membrane proteins.29,30

SCG is also believed to interfere with inflammatory
processes in asthma by inhibiting the activation of
important inflammatory cells, such as eosinophils
and monocytes, and eosinophil chemotaxis induced
by platelet activating factor.31 Finally, prevention
against capsaicin-substance P-induced broncho-
constriction in dogs and bronchospasm caused by
sulphur dioxide, metabisulphites and isocyanates in
human beings, are thought to be due to a blocking
effect on neural reflex bronchoconstriction.32

The effectiveness of SCG in the treatment of child-
hood asthma has been well documented in several
clinical studies. When administered regularly, it
decreases respiratory symptom scores and the need for
adjunctive anti-asthma medications such as theophylline,
β₂-agonists and corticosteroids.33 Improvement in asthma control by SCG is thought to be
largely dependent on its capacity to modulate non-
specific bronchial hyper-responsiveness at therapeu-
tic doses.

For practical purposes, it is useful to analyse the
studies on the effect of SCG on BHR by dividing them
into short-term and long-term studies. In the former,
acute protection is determined by the shift of the
dose–response curve immediately after drug ad-
ministration. In the latter, BHR is measured after
several weeks (or months) of treatment.

| TABLE 1. Mechanisms of action of sodium cromoglycate and nedocromil sodium |
|---------------------------------------------|
| Sodium cromoglycate                        |
| Stabilization of mast cell membrane         |
| Protein phosphorylation                     |
| Inhibition of the activation of inflammatory cells |
| Inhibition of the effects of cell mediators  |
| Inhibition of neutrophil-induced neural reflex bronchoconstriction |
| Nedocromil sodium                           |
| Stabilization of mast cell membrane         |
| Inhibition of mediator release by inflammatory cells |
| Inhibition of neutrophil and eosinophil chemotaxis induced by PAF |
| Inhibition of protein kinase C              |
| Inhibition of neuropeptide release from sensory nerves |

(Modified from: Bernstein JA and Berstein IL. Cromolyn and nedocromil. Novel anti-allergic drugs. *Immunol Allergy Clin N Am* 1993; 13: 891–902.)
Cromoglycate, nedocromil and airway reactivity

SCG inhibits both the early and late phase airway response when administered before allergen challenge and this is associated with an inhibitory effect on the allergen-induced hyper-responsiveness. Administration of SCG after the early response, but at least 60 min before the late response to allergen, caused a significant delay of LAR onset and a reduction in its duration. Furthermore, the allergen-induced increase in methacholine responsiveness was also prevented.

Short-term studies which evaluated the protective effect of SCG against nonantigenic bronchial challenges showed variable results, depending on the bronchoprovocative agent utilized. Acute protection of SCG (40 mg, 10 min before challenge) to methacholine and histamine was observed by Woenne et al. in 60% of a group of children with asthma. Mean change in BHR was +1.3 doubling doses (DD) and 0.8 DD when tested by methacholine and histamine, respectively. On the other hand, Cockcroft et al., Griffin et al. and Lemire et al. failed to observe any significant protection of short-term SCG against BHR to histamine or methacholine.

SCG has a well-documented preventive effect against bronchoconstriction induced by exercise, cold air and nonisotonic aerosol inhalation. SCG is also more effective than atropine in preventing the asthmatic response to sulphur dioxide which is mediated by atropine-sensitive mechanisms, probably through irritant airway receptors.

Long-term studies substantially confirmed the protective effect of SCG against allergen inhalation challenge (2-4 weeks of administration) and cold air (4 weeks). In exercise-induced bronchoconstriction, the drug effectiveness was unaffected by its chronic use (1 year). The results of chronic dosing of SCG upon histamine and methacholine challenge were conflicting when SCG was used for up to 8 weeks. Lack of activity was reported by some authors, while positive results—especially for 6 to 8 week studies—were observed by other investigators. Conflicting results disappear when SCG is used chronically for more than 8 weeks. In such a case, a significant reduction of BHR, as measured by histamine or methacholine challenge, has been reported by most authors.

Nedocromil sodium

Although nedocromil sodium (NS) differs structurally from SCG, they have many common mechanisms of action (Table 1). NS reduces both early and late airway responses to allergen challenge by inhibiting mediator release from a variety of inflammatory cells. It inhibits histamine secretion from both human BAL and dispersed lung mast cells, but its apparent activity varies markedly and inversely with the strength of the secretory stimulus. NS also inhibits the release of PGD2 from human lung mast cells and strongly decreases in vitro neutrophil and eosinophil mobilization caused by different chemotactic factors such as PAF and LTB4. In an in vitro model of human bronchial tissue, NS inhibited the hyper-responsiveness induced by ionophore activated neutrophils presumably by modulating the release of prostaglandins and/or thromboxane A2 from inflammatory cells. NS also induces a significant inhibition of generation of cytotoxic mediators from both human monocytes and alveolar macrophages and of the release of leukotrienes and 5-HETE from alveolar macrophages. In human neutrophils, a dose-dependent interference with N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced superoxide anion production and with FMLP binding was observed. Finally, the inhibition of bronchoconstriction induced by inhaled bradykinin sulphur dioxide, metabisulphite and ultrasonically nebulized water suggests that NS prevents sensitization and activation of airway sensory nerves.

Clinical studies on the use of NS in patients with asthma have generally demonstrated a beneficial effect on respiratory symptoms and function similar to those obtained with SCG. Single-dose studies confirmed that NS significantly protects against allergen, fog and exercise challenge. In exercise-induced bronchoconstriction in children, NS is more effective than the calcium antagonists verapamil and ipratropium bromide, but is comparable with SCG. NS seems to offer a better prevention than SCG against inhaled adenosine, sulphur dioxide and cold air. Recently, it was shown that in nonasthmatic, nonatopic subjects, NS administration for 4 days significantly inhibited a PAF-induced increase in airway reactivity to methacholine. Long-term (8 weeks) treatment with NS or beclomethasone resulted in a comparable decrease of BHR to methacholine in nonatopic asthmatic adults but, in another study, an 8-week treatment with beclomethasone was reported to be superior to treatment with NS with regard to BHR to histamine and distilled water in atopic asthmatic adults. A decrease in histamine responsiveness was also observed when NS was used for 4 weeks during seasonal allergen exposure but no change was reported in 120 clinically stable asthmatic children, when challenged after NS administration for 8 weeks, despite improving pulmonary function in those with abnormal baseline levels. Finally, experimental data suggest that NS and beclomethasone probably reduce BHR by different mechanisms. This view is supported by the fact that addition of NS to inhaled corticosteroids can improve clinical symptoms and respiratory function in steroid-dependent adult patients.
Conclusions

Airway inflammation and the release of mediators from inflammatory cells have recently received attention as important factors in the pathogenesis of BHR in asthmatic patients. Consequently, a wider use of antiallergic drugs for the long-term treatment of asthma seems advisable. Although there is increasing recognition that BHR and asthma are not synonymous, the capacity of a drug to reduce BHR under different immunologic and experimental conditions can be still considered a useful method to explore its clinical efficacy. SCG and NS demonstrated, both in vitro and in vivo, a good antiasthmatic/anti-inflammatory activity and they offer protection against various inhalation challenges, both immunologic and nonimmunologic. The results of the available studies suggest that SCG and NS can be safely considered in the choice of a first-line therapy for the maintenance treatment of mild-to-moderate asthma.

References

1. Hargave PE, Gibson PG, Ramsdale EH. Airway hyper-responsiveness, airway inflammation, and asthma. Immunol Allergy Clin N Am 1990; 10: 459-468.

2. Hargave PE, Dolovich J, O’Byrne PM, et al. The origin of airway hyper-responsiveness. J Allergy Clin Immunol 1990; 86: 825-832.

3. Martinez FD, Morgan WJ, Wright AL, et al. Diminished lung function predicts persistent asthma in childhood. J Allergy Clin Immunol 1993; 92: 155-158.

4. Scholsberg M, Liu MC, Bochner BS. Pathophysiology of asthma. Immunol Allergy Clin N Am 1993; 13: 721-743.

5. Platt-Mills TAE, Tovey ER, Mitchell EB, et al. Reduction of bronchial hyper-responsiveness in two populations of Australian schoolchildren. ILAR J 1987; 29: 195-200.

6. Plant-Mills TAE, Tovey RB, Mitchell EB, et al. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 1982; ii: 675-678.

7. Boner AL, Niero E, Antolini I, et al. Pulmonary function and bronchial hyper-responsiveness in atopic children. J Allergy Clin Immunol 1989; 84: 1165-1173.

8. Peat JK, Bolton WT, Salome CM, et al. Bronchial hyperresponsiveness in early infancy. N Engl J Med 1984; 310: 179-184.

9. Young S, Le Souef PN, Geelhoed GC, et al. The influence of a family history of asthma and parental smoking on airway responsiveness in early infancy. N Engl J Med 1991; 324: 1168-1173.

10. Harries MG. Bronchial irritant receptors and possible action for cromolyn sodium. Am Rev Respir Dis 1980; 121: 389-413.

11. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

12. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

13. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

14. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

15. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

16. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

17. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

18. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

19. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1988; 138: 1112-1137.

20. Robertson DG, Kerigan AT, Hargreave FE, Dolovich J. Latent asthmatic responses induced by ragweed pollens. J Allergy Clin Immunol 1974; 54: 234-254.

21. Durham SR. Late onset reactions. In: Morton J, ed. Preventive Therapy in Asthma. London: Academic Press, 1989: 135-140.

22. O’Byrne PM, Dolovich J, Hargave PE. Late asthmatic responses. Am Rev Respir Dis 1987; 136: 740-751.

23. Virant FS, Bierman CW. The role of the neutrophil in the late-phase asthmatic reaction and airway hyperresponsiveness. Immunol Allergy Clin N Am 1990; 10: 483-501.
57. Bruijnzeel PLB, Werringa RAJ, Kok TM, et al. Effects of nedocromil sodium on in vitro induced migration, activation and mediator release from human granulocytes. *J Allergy Clin Immunol* 1993; 92: 159-164.
58. Hughes JM, McKay KO, Johnson PR, et al. Neutrophil-induced human bronchial hyper-responsiveness in vitro—pharmacological modulation. *Clin Exp Allergy* 1993; 23: 251-256.
59. Joseph M, Tsiropoulos A, Tonnell A-B, Capron A. Modulation by nedocromil sodium of immunologic and nonimmunologic activation of monocytes, macrophages and platelets. *J Allergy Clin Immunol* 1993; 92: 165-170.
60. González JP, Bredgen BN. Nedocromil sodium: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airway disease. *Drugs* 1987; 34: 560-577.
61. Peroni DG, Melotti P, Piacentini GL, et al. Effects of nedocromil sodium on the binding of N-formyl-methionyl-leucyl-phenylalanine in human neutrophils. *Agents Action* 1992; 36: 212-214.
62. Peroni DG, Piacentini GL, Melotti P, Boner AL. Inhibition by nedocromil sodium of superoxide anion production in human neutrophils. A preliminary communication. *Drug Invest* 1992; 4: 395-390.
63. Barnes PJ. Effect of nedocromil sodium on airway sensory nerves. *J Allergy Clin Immunol* 1993; 92: 182-186.
64. Nair N, Hopp R, Townley R. Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects. *Ann Allergy* 1986; 56: 325-331.
65. Debelle M. Nedocromil sodium and exercise-induced asthma in adolescents. *Eur Resp J* 1986; 69 (Suppl 17): 266-267.
66. Roberts R, Vaghi A, Simone P, et al. Prevention of fog-induced bronchospasm by nedocromil sodium. *Clin Allergy* 1987; 17: 69-74.
67. Boner AL, Vallone G, Bennati D. Nedocromil sodium in exercise-induced bronchoconstriction in children. *Ann Allergy* 1986; 56: 39-41.
68. Coletti A, Valletta EA, Sette L, et al. Comparison of nedocromil sodium and sodium cromoglycate administered by pressurized aerosol, with and without a spacer device in exercise-induced asthma in children. *Eur Resp J* 1993; 6: 525-526.
69. Crimi N, Palermo F, Olivieri R, et al. Adenosine-induced bronchoconstriction: comparison between nedocromil and sodium cromoglycate. *Eur Resp J* 1986; 69 (Suppl 147): 258-262.
70. Altounyan RC, Cole M, Lee TB. Inhibition of sulphur dioxide induced bronchoconstriction by nedocromil sodium and sodium cromoglycate in non-asthmatic anopic subjects. *Eur Resp J* 1986; 69 (Suppl 147): 274-276.
71. Dí Maria GU, Bellofatto S, Caneco N, et al. Nedocromil sodium inhibits the increase in airway reactivity induced by platelet activating factor in humans. *Clin Allergy* 1992; 22: 129-128.
72. Bel EH, Thummes MC, Hermans J, et al. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. *Am Rev Respir Dis* 1990; 142: 21-28.
73. Grooth CAR, Lamens J, Vidal P, et al. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyper-responsiveness to histamine and distilled water. *Eur Resp J* 1992; 5: 1075-1083.
74. Dorward AJ, Roberts JA, Thomson NC. Effect of nedocromil sodium on histamine airway reactivity in grass-pollen sensitive asthmatics during the pollen season. *Clin Allergy* 1986; 16: 309-316.
75. Foo AL, Lantieri Q, Bartin PR, et al. The effect of nedocromil sodium on histamine responsiveness in clinically stable asthmatic children. *J Asthma* 1993; 30: 381-390.
76. Bianco S, del Bonio N, Grassi V, Orefico U. Effectiveness of nedocromil sodium versus placebo in addition to routine asthma maintenance therapy: a multicentre, double-blind, placebo-controlled study. *Thomx* 1989; 44: 654-659.
77. Rebuff S, Kesten S, Boulet PS, et al. A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group. *J Allergy Clin Immunol* 1993; 92: 612-617.